These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 22458919)
1. Skin reactions in a phase 3 study of a testosterone topical solution applied to the axilla in hypogonadal men. Muram D; Melby T; Alles Kingshill E Curr Med Res Opin; 2012 May; 28(5):761-6. PubMed ID: 22458919 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of the 2% formulation of testosterone topical solution applied to the axillae in androgen-deficient men. Wang C; Ilani N; Arver S; McLachlan RI; Soulis T; Watkinson A Clin Endocrinol (Oxf); 2011 Dec; 75(6):836-43. PubMed ID: 21689131 [TBL] [Abstract][Full Text] [Related]
3. Tretinoin gel microspheres 0.04% versus 0.1% in adolescents and adults with mild to moderate acne vulgaris: a 12-week, multicenter, randomized, double-blind, parallel-group, phase IV trial. Berger R; Rizer R; Barba A; Wilson D; Stewart D; Grossman R; Nighland M; Weiss J Clin Ther; 2007 Jun; 29(6):1086-97. PubMed ID: 17692723 [TBL] [Abstract][Full Text] [Related]
4. Testosterone topical solution (Axiron) for hypogonadism. Med Lett Drugs Ther; 2011 Jul; 53(1368):54-5. PubMed ID: 21738108 [TBL] [Abstract][Full Text] [Related]
5. Serum testosterone levels in non-dosed females after secondary exposure to 1.62% testosterone gel: effects of clothing barrier on testosterone absorption. Stahlman J; Britto M; Fitzpatrick S; McWhirter C; Testino SA; Brennan JJ; Zumbrunnen TL Curr Med Res Opin; 2012 Feb; 28(2):291-301. PubMed ID: 22188558 [TBL] [Abstract][Full Text] [Related]
6. [Scrotal testosterone patches: a good addition to therapeutic options for hypogonadal men]. Asscheman H; Gooren LJ Ned Tijdschr Geneeskd; 2000 Apr; 144(18):847-50. PubMed ID: 10816775 [TBL] [Abstract][Full Text] [Related]
7. The long-term efficacy and safety of a testosterone mucoadhesive buccal tablet in testosterone-deficient men. Dinsmore WW; Wyllie MG BJU Int; 2012 Jul; 110(2):162-9. PubMed ID: 22288877 [TBL] [Abstract][Full Text] [Related]
8. One-year efficacy and safety study of a 1.62% testosterone gel in hypogonadal men: results of a 182-day open-label extension of a 6-month double-blind study. Kaufman JM; Miller MG; Fitzpatrick S; McWhirter C; Brennan JJ J Sex Med; 2012 Apr; 9(4):1149-61. PubMed ID: 22321357 [TBL] [Abstract][Full Text] [Related]
9. Effects of skin washing on systemic absorption of testosterone in hypogonadal males after administration of 1.62% testosterone gel. Stahlman J; Britto M; Fitzpatrick S; McWhirter C; Testino SA; Brennan JJ; Zumbrunnen TL Curr Med Res Opin; 2012 Feb; 28(2):271-9. PubMed ID: 22185431 [TBL] [Abstract][Full Text] [Related]
10. Long-term tolerability of the methylphenidate transdermal system in pediatric attention-deficit/hyperactivity disorder: a multicenter, prospective, 12-month, open-label, uncontrolled, phase III extension of four clinical trials. Findling RL; Wigal SB; Bukstein OG; Boellner SW; Abikoff HB; Turnbow JM; Civil R Clin Ther; 2009 Aug; 31(8):1844-55. PubMed ID: 19808143 [TBL] [Abstract][Full Text] [Related]
11. A novel testosterone 2% gel for the treatment of hypogonadal males. Dobs AS; McGettigan J; Norwood P; Howell J; Waldie E; Chen Y J Androl; 2012; 33(4):601-7. PubMed ID: 21979302 [TBL] [Abstract][Full Text] [Related]
12. A small-scale clinical trial to determine the safety and efficacy of testosterone replacement therapy in hypogonadal men with spinal cord injury. Bauman WA; Cirnigliaro CM; La Fountaine MF; Jensen AM; Wecht JM; Kirshblum SC; Spungen AM Horm Metab Res; 2011 Jul; 43(8):574-9. PubMed ID: 21717386 [TBL] [Abstract][Full Text] [Related]
13. Testosterone treatment comes of age: new options for hypogonadal men. Nieschlag E Clin Endocrinol (Oxf); 2006 Sep; 65(3):275-81. PubMed ID: 16918944 [TBL] [Abstract][Full Text] [Related]
14. Utility of a single serum testosterone measurement to determine response to topical testosterone replacement in hypogonadal men. Muram D; Ni X Curr Med Res Opin; 2016; 32(2):263-9. PubMed ID: 26549704 [TBL] [Abstract][Full Text] [Related]
15. Transdermal testosterone gel: pharmacokinetics, efficacy of dosing and application site in hypogonadal men. Meikle AW; Matthias D; Hoffman AR BJU Int; 2004 Apr; 93(6):789-95. PubMed ID: 15049991 [TBL] [Abstract][Full Text] [Related]
16. Use of topical corticosteroid pretreatment to reduce the incidence and severity of skin reactions associated with testosterone transdermal therapy. Wilson DE; Kaidbey K; Boike SC; Jorkasky DK Clin Ther; 1998; 20(2):299-306. PubMed ID: 9589821 [TBL] [Abstract][Full Text] [Related]
17. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison. Likar R; Lorenz V; Korak-Leiter M; Kager I; Sittl R Clin Ther; 2007 Aug; 29(8):1591-606. PubMed ID: 17919542 [TBL] [Abstract][Full Text] [Related]
18. Comparability of single measurements of serum testosterone to the 24-hour C(avg) in patients using testosterone 2% solution. Muram D; Baygani S J Sex Med; 2014 Nov; 11(11):2826-9. PubMed ID: 25123851 [TBL] [Abstract][Full Text] [Related]
19. Testosterone therapy in men with Parkinson disease: results of the TEST-PD Study. Okun MS; Fernandez HH; Rodriguez RL; Romrell J; Suelter M; Munson S; Louis ED; Mulligan T; Foster PS; Shenal BV; Armaghani SJ; Jacobson C; Wu S; Crucian G Arch Neurol; 2006 May; 63(5):729-35. PubMed ID: 16682542 [TBL] [Abstract][Full Text] [Related]
20. Effect of application site, clothing barrier, and application site washing on testosterone transfer with a 1.62% testosterone gel. Stahlman J; Britto M; Fitzpatrick S; McWhirter C; Testino SA; Brennan JJ; Zumbrunnen TL Curr Med Res Opin; 2012 Feb; 28(2):281-90. PubMed ID: 22188557 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]